Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Efgartigimod Alfa in Myasthenia Gravis: NCT06587867 Clinical Landscape Report 2026
28 September 2026
NCT06587867 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pemafibrate in Hypertriglyceridemia: NCT06623539 Clinical Landscape Report 2026
28 September 2026
NCT06623539 clinical landscape for Hypertriglyceridemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zinc Oxide in Idiopathic Pulmonary Fibrosis: ACTRN12624001171505 Clinical Landscape Report 2026
28 September 2026
ACTRN12624001171505 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Survodutide in Metabolic Dysfunction Associated Steatohepatitis: NCT06632457 Clinical Landscape Report 2026
28 September 2026
NCT06632457 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
GSK3915393 in Idiopathic Pulmonary Fibrosis: NCT06625489 Clinical Landscape Report 2026
28 September 2026
NCT06625489 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mosliciguat in Familial Hypersensitivity Pneumonitis: NCT06635850 Clinical Landscape Report 2026
28 September 2026
NCT06635850 clinical landscape for Familial Hypersensitivity Pneumonitis: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
BI-770371 in Metabolic Dysfunction Associated Steatohepatitis: NCT06675929 Clinical Landscape Report 2026
28 September 2026
NCT06675929 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Admilparant in Lung Diseases: CTRI/2024/11/076288 Clinical Landscape Report 2026
28 September 2026
CTRI/2024/11/076288 clinical landscape for Lung Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Survodutide in Fibrosis, Liver: NCT06632444 Clinical Landscape Report 2026
28 September 2026
NCT06632444 clinical landscape for Fibrosis, Liver: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BAR-502 in Metabolic Dysfunction Associated Steatohepatitis: NCT06705998 Clinical Landscape Report 2026
28 September 2026
NCT06705998 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Vitamin E Nicotinicate in Metabolic Dysfunction Associated Steatohepatitis: NCT06677788 Clinical Landscape Report 2026
28 September 2026
NCT06677788 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
PIPE-791 in Idiopathic Pulmonary Fibrosis: NCT06683612 Clinical Landscape Report 2026
28 September 2026
NCT06683612 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.